Bank of America just raised its EUR/USD forecast
Philip Tsai, the Chief Technology Officer of Immunome Inc . (NASDAQ:IMNM), has recently acquired a significant number of shares in the company. According to an SEC filing dated March 25, 2025, Tsai purchased 12,300 shares of Immunome’s common stock on March 24, 2025. The shares were bought at a price of $8.42 each, amounting to a total transaction value of $103,566. This purchase comes as the stock has experienced significant volatility, with shares down over 66% in the past year and currently trading at $6.94.
Following this transaction, Tsai’s total holdings in Immunome have increased to 33,300 shares. This move underscores a notable investment by a key executive in the company, reflecting potential confidence in Immunome’s future performance. Analysts share this optimism, with price targets ranging from $20 to $38 per share. InvestingPro analysis reveals 8 additional key insights about Immunome’s financial health and market position, including important metrics about its cash position and growth prospects.
In other recent news, Immunome Inc. has been in the spotlight following several key developments. The company recently reported its fourth-quarter 2024 earnings, with results aligning with previous disclosures. Guggenheim Securities responded by lowering Immunome’s price target from $35.00 to $25.00, while maintaining a Buy rating. The adjustment reflects the dilution effects of recent financing, although this was partially offset by an increased probability of success for their candidate IM-1021.
In addition, Immunome announced an upsized public offering of common stock priced at $7.75 per share, expected to generate gross proceeds of approximately $150 million. The offering, managed by J.P. Morgan, TD Cowen, Leerink Partners, and Guggenheim Securities, aims to support ongoing research and development. Immunome’s pipeline is robust, with key assets like varegacestat in a Phase 3 trial and IM-1021 poised to begin a Phase 1 trial in early 2025.
Moreover, Immunome disclosed preliminary financial estimates, projecting around $217.3 million in cash and equivalents as of December 31, 2024. The company also shared updates on its preclinical assets, including several antibody-drug conjugates targeting solid tumors. In executive news, Immunome offered a substantial relocation package to CFO Max Rosett, underscoring the company’s commitment to its leadership team. These recent developments highlight Immunome’s strategic efforts to advance its oncology pipeline and strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.